The development of abiraterone acetate for castration-resistant prostate cancer

被引：16

作者：

Grist, Emily ^{[1
,2
]}

Attard, Gerhardt ^{[1
,2
]}

机构：

[1] Inst Canc Res, London SW3 6JB, England

[2] Royal Marsden NHS Fdn Trust, London, England

来源：

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | 2015年 / 33卷 / 06期

关键词：

HUMAN CYTOCHROME P450(17-ALPHA); ANDROGEN-RECEPTOR GENE; I CLINICAL-TRIAL; ANTITUMOR-ACTIVITY; STEROIDAL INHIBITORS; INCREASED SURVIVAL; PLUS PREDNISONE; DOUBLE-BLIND; DOCETAXEL; ENZALUTAMIDE;

D O I：

10.1016/j.urolonc.2015.03.021

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Abiraterone acetate is a novel CYP17A1 inhibitor demonstrated to prolong survival in castration-resistant prostate cancer (CRPC). This review explores key stages in the almost 20-year history of abiraterone acetate's development, starting with a program aiming to develop inhibitors of androgen synthesis at the Institute of Cancer Research, London. Clinical development was initially slow owing to insufficient data supporting targeting of androgen synthesis as a therapeutic approach in CRPC and safety concerns of adrenocortical insufficiency from suppression of cortisol. Regulatory authorities approved abiraterone acetate in 2011 after a survival benefit was demonstrated when given in combination with prednisone as compared with prednisone alone in docetaxel-treated men. Licensing approval extended to include chemotherapy-naive patients with CRPC in 2012 following a significant increase in radiographic progression-free survival. Ongoing research focuses on identifying predictive biomarkers and understanding mechanisms of resistance to improve its administration. (C) 2015 Elsevier Inc. All rights reserved.

引用

页码：289 / 294

页数：6

共 44 条

[1]

[Anonymous], 2011, CANC RISK

[2] AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer [J].

Antonarakis, Emmanuel S. ;

Lu, Changxue ;

Wang, Hao ;

Luber, Brandon ;

Nakazawa, Mary ;

Roeser, Jeffrey C. ;

Chen, Yan ;

Mohammad, Tabrez A. ;

Chen, Yidong ;

Fedor, Helen L. ;

Lotan, Tamara L. ;

Zheng, Qizhi ;

De Marzo, Angelo M. ;

Isaacs, John T. ;

Isaacs, William B. ;

Nadal, Rosa ;

Paller, Channing J. ;

Denmeade, Samuel R. ;

Carducci, Michael A. ;

Eisenberger, Mario A. ;

Luo, Jun .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) :1028-1038

[3] Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade [J].

Arora, Vivek K. ;

Schenkein, Emily ;

Murali, Rajmohan ;

Subudhi, Sumit K. ;

Wongvipat, John ;

Balbas, Minna D. ;

Shah, Neel ;

Cai, Ling ;

Efstathiou, Eleni ;

Logothetis, Chris ;

Zheng, Deyou ;

Sawyers, Charles L. .

CELL, 2013, 155 (06) :1309-1322

[4] Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven [J].

Attard, Gerhardt ;

Reid, Alison H. M. ;

Yap, Timothy A. ;

Raynaud, Florence ;

Dowsett, Mitch ;

Settatree, Sarah ;

Barrett, Mary ;

Parker, Christopher ;

Martins, Vanessa ;

Folkerd, Elizabeth ;

Clark, Jeremy ;

Cooper, Colin S. ;

Kaye, Stan B. ;

Dearnaley, David ;

Lee, Gloria ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) :4563-4571

[5] Overcoming mutation-based resistance to antiandrogens with rational drug design [J].

Balbas, Minna D. ;

Evans, Michael J. ;

Hosfield, David J. ;

Wongvipat, John ;

Arora, Vivek K. ;

Watson, Philip A. ;

Chen, Yu ;

Greene, Geoffrey L. ;

Shen, Yang ;

Sawyers, Charles L. .

ELIFE, 2013, 2

[6] PHARMACOLOGY OF NOVEL STEROIDAL INHIBITORS OF CYTOCHROME P450(17-ALPHA) (17-ALPHA-HYDROXYLASE C17-20 LYASE) [J].

BARRIE, SE ;

POTTER, GA ;

GODDARD, PM ;

HAYNES, BP ;

DOWSETT, M ;

JARMAN, M .

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1994, 50 (5-6) :267-273

[7] Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone [J].

Bianchini, D. ;

Lorente, D. ;

Rodriguez-Vida, A. ;

Omlin, A. ;

Pezaro, C. ;

Ferraldeschi, R. ;

Zivi, A. ;

Attard, G. ;

Chowdhury, S. ;

de Bono, J. S. .

EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) :78-84

[8] Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors [J].

Cai, Changmeng ;

Chen, Sen ;

Ng, Patrick ;

Bubley, Glenn J. ;

Nelson, Peter S. ;

Mostaghel, Elahe A. ;

Marck, Brett ;

Matsumoto, Alvin M. ;

Simon, Nicholas I. ;

Wang, Hongyun ;

Chen, Shaoyong ;

Balk, Steven P. .

CANCER RESEARCH, 2011, 71 (20) :6503-6513

[9] Tumor clone dynamics in lethal prostate cancer [J].

Carreira, Suzanne ;

Romanel, Alessandro ;

Goodall, Jane ;

Grist, Emily ;

Ferraldeschi, Roberta ;

Miranda, Susana ;

Prandi, Davide ;

Lorente, David ;

Frenel, Jean-Sebastien ;

Pezaro, Carmel ;

Omlin, Aurelius ;

Rodrigues, Daniel Nava ;

Flohr, Penelope ;

Tunariu, Nina ;

de Bono, Johann S. ;

Demichelis, Francesca ;

Attard, Gerhardt .

SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (254)

[10] 3- and 4-pyridylalkyl adamantanecarboxylates: Inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C-17,C-20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer [J].

Chan, FCY ;

Potter, GA ;

Barrie, SE ;

Haynes, BP ;

Rowlands, MG ;

Houghton, J ;

Jarman, M .

JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (17) :3319-3323

← 1 2 3 4 5 →